Abstract
Prostate cancer (PCa) is the most common cancer among Canadian men (excluding nonmelanoma skin cancers) and is the third leading cause of death from cancer in men in Canada. It is estimated that, in 2020, 23,300 men will be diagnosed with PCa, representing 20% of all new cancer cases in men.1 The recommended technique being used for the detection and risk stratification of PCa is multiparametric MRI (mpMRI), which includes high-resolution T2-weighted (T2W) images to depict prostate anatomy and two functional MRI techniques, including diffusion-weighted imaging (DWI) to display cell density and dynamic contrast-enhanced MRI (DCE) that shows vascularity.2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
